HungaryHungary

Cutting-edge biotech production facility planned in Debrecen

20.10.2008

Debrecen/Budapest – Hungary’s leading pharmaceutical company Gedeon Richter Plc. is continuing to expand its activities in biotechnological R&D and manufacturing of therapeutic proteins. After the establishment of Richter-Helm in Germany, a joint venture of Gedeon Richter and Hamburg-based Helm AG one year ago, the Hungarian company announced in August that it will build a a63m multi-purpose plant for the production of biopharmaceuticals in insect and mammalian cells at Debrecen. The company says that the novel unit, which will create 110 new jobs and is expected to be operational by 2012, will be “one of kind in Central and Eastern Europe, and will also be a significant step forward in enhancing the competitiveness of Hungary.”

Plant to go online by 2012

Gedeon Richter, which will start construction of the new production plant in Debrecen’s industrial park this year, did not discuss how much money the Hungarian government will contribute to the prestigous project. But local authorities might have sold Richter the land under market prices and granted a local tax concession, according to reports from the regional press.
Besides the production of therapeutic proteins in insect and mammalian cells, the GMP-compliant plant will also be suitable for other technologies with minimal modification, according to Gedeon Richter. Initially, the new site will produce clinical trials materials, but from 2014 the company plans to switch to production of drugs for the pharmaceutical market.

HungaryHungary

19.03.2008

Budapest – A Hungarian research consortium has been granted a 3-year fund of EUR2m by the Hungarian government to identify new enzyme targets against multi-restistant strains of the tuberculosis agent Mycobacterium tuberculosis...

HungaryHungary

19.02.2008

Debrecen – Israeli generic drugmaker Teva Pharmaceutical Industries is looking to expand its presence in Hungary. The pharma company wants to double capacity at its plant in Debrecen. This will involve a EUR70 million investment...

HungaryHungary

01.01.2008

Szeged – The development of inhibitors directed against matrix metalloproteinases is at the centre of a new funding project sponsored by the Hungarian National Office for Research and Technology (NKTH). The NKTH recently granted...

HungaryHungary

22.11.2007

Budapest/Mumbai – Solvo Biotechnology (Budapest) and Krishgen BioSystems (Mumbai, India) have formed a partnership to distribute and represent Solvo’s membrane transporter assay products and services in India. “Membrane...

HungaryHungary

24.09.2007

Sofia – Icelandic Actavis Group announced double-digit growth in Bulgaria in the first half of 2007. Sales were up 10,65% with more than €23.1 million and 24 new products launched in the first six months of 2007. “Actavis...

HungaryHungary

11.07.2007

Budapest – A new National Alliance for Rare Diseases in Hungary, termed Huferdis – Rare Diseases Hungary (Hungarian Federation of People with Rare and Congenital Diseases), was announced at the beginning of June. “The importance...

HungaryHungary

16.03.2007

Budapest – The EU Environment Council, made up of the European Ministers for the Environment, rejected the proposal in February from the European Commission to lift the Hungarian prohibition to grow genetically modified maize...

HungaryHungary

21.11.2006

Gödöllö – At the end of September, GlaxoSmithKline (GSK) inaugurated a new a100-million vaccine production plant 30 km northeast of the Hungarian capital.According to GSK, the new facility will be one of Europe’s most advanced...

HungaryHungary

21.07.2006

Sofia – On June 1 a law banning the production and sale of a range of genetically modified organisms (GMOs), including wheat, came into effect in Bulgaria. The law represents an about-face for the country, which has experimented...

Displaying results 21 to 30 out of 89

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-hungary/browse/2/article/cutting-edge-biotech-production-facility-planned-in-debrecen.html

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • PROTHENA PLC (IE)18.44 USD6.84%
  • WILEX (D)3.28 EUR5.47%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • HYBRIGENICS (F)1.71 EUR-8.56%

TOP

  • WILEX (D)3.28 EUR331.6%
  • SANTHERA (CH)69.50 CHF133.2%
  • ADDEX (CH)4.21 CHF95.8%

FLOP

  • MERCK KGAA (D)63.45 EUR-50.2%
  • THROMBOGENICS (B)8.55 EUR-40.5%
  • HYBRIGENICS (F)1.71 EUR-34.5%

TOP

  • SANTHERA (CH)69.50 CHF3375.0%
  • GW PHARMACEUTICALS (UK)415.25 GBP765.1%
  • SKYEPHARMA PLC (UK)260.00 GBP314.3%

FLOP

  • CYTOS (CH)0.27 CHF-92.1%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.55 EUR-72.1%

No liability assumed, Date: 22.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events